. 2019 Jun 7;19:49. doi: 10.1186/s12894-019-0481-5

Table 3.

Meta-regression and subgroup analyses of pooled hazard ratios for progression-free survival

Subgroup	Meta-regression							Pooled HR of PFS		Heterogeneity
Subgroup	No. of studies	Coefficient	Standard error	T value	P value	Tau²	Adjusted R²	HR (95% CI)	P value	I²	P value
Year	20	0.060	0.228	0.26	0.795	0.182	−8.86%
2011–2014								0.56 (0.40–0.77)	<0.001	83.00%	<0.001
2015–2017								0.61 (0.48–0.77)	<0.001	73.60%	<0.001
Sample size	20	0.507	0.197	2.57	0.019	0.122	27.34%
<200								0.43 (0.30–0.61)	<0.001	72.10%	<0.001
≥200								0.73 (0.60–0.89)	0.002	75%	<0.001
Gender (male/female ratio)	20	−0.117	0.228	−0.51	0.614	0.177	−5.64%
<2.5								0.66 (0.53–0.82)	<0.001	54.50%	0.025
≥2.5								0.55 (0.40–0.74)	<0.001	84.70%	<0.001
Mean age	20	0.320	0.264	2.21	0.241	0.156	6.69%
<60								0.44 (0.23–0.86)	0.015	89.40%	<0.001
≥60								0.64 (0.53–0.78)	<0.001	69.70%	<0.001
Country	20	0.168	0.301	0.56	0.584	0.173	−3.31%
the USA, Europe								0.60 (0.49–0.74)	<0.001	81.40%	<0.001
Asia								0.51 (0.31–0.83)	0.006	39.50%	0.158
ECOG PS (grade 0%)	20	0.036	0.133	0.27	0.79	0.182	−8.59%
<0.5								0.35 (0.14–0.89)	0.028	87.20%	<0.001
≥0.5								0.64 (0.52–0.79)	<0.001	71.90%	<0.001
MSKCC score (favorable%)	20	0.231	0.111	2.08	0.052	0.123	26.74%
<0.25								0.43 (0.21–0.87)	0.019	76%	0.002
≥0.25								0.86 (0.73–1.02)	0.076	40.30%	0.137
Histology (clear cell%)	20	−0.139	0.126	−1.11	0.283	0.166	1.11%
<0.9								0.53 (0.39–0.71)	<0.001	29.30%	0.226
≥0.9								0.51 (0.33–0.79)	0.002	87.90%	<0.001
Prior nephrectomy (%)	20	−0.162	0.129	−1.25	0.226	0.166	1.16%
<0.9								0.52 (0.40–0.67)	0.296	17.50%	<0.001
≥0.9								0.52 (0.33–0.81)	<0.001	89.30%	0.005
No. of disease sites (1%)	20	−0.253	0.139	−1.81	0.086	0.144	13.81%
<0.2								0.41 (0.28–0.60)	<0.001	62.40%	0.047
≥0.2								0.52 (0.37–0.74)	<0.001	0	0.594
Type of analysis	20	−0.030	0.231	−0.13	0.898	0.182	−8.91%
Univariate								0.59 (0.42–0.82)	0.002	82.70%	<0.001
Multivariate								0.58 (0.46–0.75)	<0.001	74.50%	<0.001
Study design	20	0.343	0.257	1.34	0.198	0.157	6.32%
Retrospective								0.54 (0.44–0.67)	<0.001	74.90%	<0.001
Prospective								0.77 (0.53–1.12)	0.175	76.20%	0.006
Type of TKIs	20	−0.073	0.114	−0.64	0.942	0.178	−10.49%
Axitinib								0.70 (0.48–1.03)	0.07	80.90%	0.001
Sorafenib								0.86 (0.65–1.13)	0.277	0	0.339
Sunitinib								0.47 (0.34–0.64)	<0.001	77.90%	<0.001
Pazopanib								0.79 (0.66–0.94)	0.010	0	1.000

No. number, HR hazard ratio, PFS progression-free survival, ECOG PS Eastern Cooperative Oncology Group performance status, MSKCC score Memorial Sloan Kettering Cancer Center score